Findings {#Sec1}
========

Background {#Sec2}
----------

Patients with stage IIIA non-small cell lung cancer (NSCLC) represent a relatively heterogeneity with ipsilateral mediastinal lymph nodes (N2) involved, and relative roles of treatment modalities are not clearly defined. Chemoradiotherapy is an important treatment for stage IIIA disease but limited by treatment-related life-threatening toxicities \[[@CR1]\]. And previous work showed that status of gene expression was related to different degrees of how much gemcitabine improved survival of patients with advanced NSCLC \[[@CR2]\]. Recently, an individual participant data meta-analysis \[[@CR3]\] found that neoadjuvant chemotherapy improves an absolute 5-year survival of 5 % and may be preferable for patients with poorer prognosis or larger tumors. However, chemotherapy has reached a therapeutic plateau in NSCLC. A literature-based meta-analysis reported \[[@CR4]\] that tyrosine kinase inhibitors (TKIs) could provide more survival benefits for patients with advanced epidermal growth factor receptor (*EGFR*) mutant NSCLC, indicating the importance of selected patients with specific mutations when exploring efficacy of targeted therapy. In patients with *EGFR* mutation positive NSCLC, an *EGFR*-TKI may provide a dramatic response in a metastatic setting \[[@CR5]--[@CR7]\]. The primary analysis in the OPTIMAL study, comparing first-line erlotinib with gemcitabine/carboplatin (GC) in patients with advanced NSCLC with *EGFR* mutations, showed relatively higher response rate of 82.9 % (68/82) and significantly longer progression-free survival (PFS) with erlotinib than with GC therapy \[[@CR8]\]. Since 2007, several case reports and retrospective studies with small sample sizes have shown that neoadjuvant *EGFR*-TKI therapy results in N2 downstaging in patients with stage IIIA-N2 NSCLC harboring *EGFR* mutation \[[@CR9]--[@CR12]\]. In two phase II studies, neoadjuvant *EGFR*-TKI showed low toxicity and sufficient activity in an enriched population \[[@CR13], [@CR14]\]. However, no survival data in neoadjuvant TKI therapy were obtained.

In the near future, lung cancer treatment will likely become more patient-tailored by a molecular-based strategy. Neoadjuvant *EGFR*-TKI therapy and customized adjuvant therapy (IFCT-0801, TASTE trial) are appealing but controversial strategies in patients with IIIA-N2 NSCLC \[[@CR15]\]. The aim of this study was to investigate the efficacy of biomarker-guided neoadjuvant treatment strategy with erlotinib versus GC regimen in patients with stage IIIA-N2 NSCLC stratified by *EGFR* activating mutations and explore a new treatment strategy for this subset of patients.

Results and discussion {#Sec3}
======================

Results {#Sec4}
-------

### Patient characteristics {#Sec5}

Twenty-four patients with IIIA-N2 NSCLC diagnosed by mediastinoscopy or endobronchial ultrasound (EBUS) were enrolled from January 2008 to May 2011. The cutoff date for PFS and overall survival (OS) data was March 22nd, 2015. The median follow-up was 24.4 months (range, 1.7--68.7 months). Twelve cases with a mutant-type *EGFR* were assigned to the erlotinib arm and 12 cases with wild type *EGFR* to the GC arm. In the erlotinib arm, two patients with *EGFR* L858R mutation also had a *KRAS* mutation or EML4-ALK translocation. No T790M mutation was found in surgical specimens after neoadjuvant erlotinib therapy. Age, gender, smoking status, histology, postoperative radiotherapy, and the median follow-up were balanced between arms. The clinical and histological data for all patients are listed in Table [1](#Tab1){ref-type="table"}.Table 1Baseline patient demographics and clinical characteristicsCharacteristicErlotinibGC*P* valueMedian age at diagnosis (years)60.17 ± 13.3158.75 ± 12.120.71Gender, *n* (%)0.68Male6 (6/12, 50.00 %)8 (8/12, 66.67 %)Female6 (6/12, 50.00 %)4 (4/12, 33.33 %)Smoking duration6.25 ± 11.8920.83 ± 21.090.10Daily cigarette consumption, *n*7.92 ± 14.9917.92 ± 18.270.18Pathology, *n* (%)1.00Adeno11 (11/12, 91.67 %)11 (11/12, 91.67 %)LCNEC0 (0.00 %)1 (1/12, 8.33 %)Adenoid cystic carcinoma1 (1/12, 8.33 %)0 (0.00 %)Mutation status, *n* (%)\<0.001EGFR/KRAS wild type011KRAS01Exon 19 deletion60L858R40EGFR mutation with KRAS codon1012/13\*EGFR mutation with EML4-ALK\*10Deletion in BIM2/80/9Postoperative radiotherapy, *n*3/62/70.59Median follow-up (months)19.3 (5.8--64.0)35.6 (1.7--68.7)0.41*EGFR* epidermal growth factor receptor, *LCNEC* large-cell neuroendocrine carcinoma, *GC* gemcitabine/carboplatin, *BIM* Bcl-2-interacting mediator of cell death\*Two patients in the erlotinib arm with the EGFR L855R mutation also had the KRAS mutation or EML4-ALK translocation

### Efficacy {#Sec6}

The overall response rate was 41.7 %(10/24). The RR was 58.3 % (7/12) in the erlotinib arm and 25.0 % (3/12) in the GC arm (*P* = 0.18). Overall, 54.2 % (13/24) patients received surgical resection. Three of six cases in the erlotinib arm and five of seven cases in the GC arm underwent complete resection (R0). The clinical N2 downstaging rate was 25.0 % (3/12) in both arms. The pathological N2 complete response rates were 16.7 % (2/12) versus 25 % (3/12) (*P* = 0.64) (Table [2](#Tab2){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}).Table 2Evaluation of neoadjuvant therapy efficacyIndexEvaluationErlotinib arm *n* = 12, (%)GC arm *n* = 12, (%)*P* valueRECISTPR7/12 (58.33)3/12 (25.00)0.18SD2/12 (16.67)6/12 (50.00)PD\*3/12 (25.00)2/12 (16.67)NA0 (0.00)1/12 (8.33)Clinical N2 downstaging3/12 (25.00)3/12 (25.00)1.00Pathological N2 downstaging2/12 (16.67)3/12 (25.00)0.64ResectionR03/6 (50.00)5/7 (71.43)0.59R13/6 (50.00)2/7 (28.57)Values are presented as *n* (percentage)*GC* gemcitabine/carboplatin, *RECIST* Response Evaluation Criteria in Solid Tumors, *PR* partial response, *SD* stable disease, *PD* progressive disease, *NA* not available\*Two patients with the EGFR L858R mutation and the KRAS mutation or EML4-ALK translocation developed primary resistance to induction erlotinibFig. 1Waterfall plot of response to neoadjuvant treatment. Abbreviations: GC, gemcitabine/carboplatin; E, erlotinib. Note: The response rate of one case in the GC arm was not available

### Survival and failure models \[[@CR16]\] {#Sec7}

Overall, the PFS and OS were 7.9 and 23.2 months, respectively (Fig. [2a](#Fig2){ref-type="fig"}). The median PFS was 6.9 months (95 % confidence interval (CI), 3.8--10.0) for erlotinib arm and 9.0 months (95 % CI, 3.1--15.0) for GC arm (*P* = 0.071). The median OS was 14.5 months (95 % CI, 1.0--28.1) for the erlotinib arm and 28.1 months (95 % CI, 0.0--66.2) for the GC arm (*P* = 0.201) (Fig. [2b, c](#Fig2){ref-type="fig"}). Among patients receiving surgery, the median PFS was 8.6 months (95 % CI, 5.8--11.3) for the erlotinib arm and 28.9 months (95 % CI, 0.0--64.0) for the GC arm (*P* = 0.018) and the median OS was 25.5 months and 57.3 months, respectively (*P* = 0.162) (Fig. [2d, e](#Fig2){ref-type="fig"}). The local recurrence rate (5/12) was similar to the distant metastasis rate (7/12) in the GC arm, whereas the common initial failure model in the erlotinib arm was distant metastasis (10/12), particularly brain metastases (3/10) and bilateral lung metastases (8/10) (Additional file [1](#MOESM1){ref-type="media"}).Fig. 2PFS and OS. **a** PFS and OS for the total population; **b** PFS comparison between two arms; **c** OS comparison between two arms; **d** PFS for the resection patients; **e** OS for the resection patients; **f** The 2nd PFS. Abbreviations: GC, gemcitabine/carboplatin; PFS, progression-free survival; OS, overall survival

### Treatment toxicity and feasibility {#Sec8}

Overall, neoadjuvant therapies were well tolerated. The most common side effects in the erlotinib arm were rash (100 %; 16.7 % as grade 3--4) and diarrhea (41.6 %). Only one case had postoperative bleeding. Another case in the erlotinib arm suffered from acute radiotherapy-induced pneumonitis related to death. Three cases in the GC arm exhibited grade 4 thrombocytopenia, two of which received blood transfusion.

### EGFR*-*TKI retreatment {#Sec9}

The second median PFS, after the first progression, was 8.0 months (95 % CI, 4.0--12.0) for the erlotinib arm and 4.0 months (95 % CI, 1.2--6.8) for the GC arm (*P* = 0.880) (Fig. [2f](#Fig2){ref-type="fig"}). In addition, all six cases undergoing R0/R1 resection in the erlotinib arm achieved PR to TKI retreatment at progression, with a median PFS of 9.4 months.

### Biomarker {#Sec10}

Genetic profiles in two arms are summarized in Additional file [1](#MOESM1){ref-type="media"}, indicating rare genetic heterogeneity between initial specimens and surgical samples after neoadjuvant therapy. There was only one patient in each arm whose gene mutation status transferred from mutant type to wild type or contrariwise. The BIM deletion polymorphism had no correlation with TKI efficacy (Additional file [1](#MOESM1){ref-type="media"}). Immunohistochemistry (IHC) was conducted to detect protein expressions on resected samples after induced elotinib therapy. In all six cases, p*EGFR* (Tyr1068) has been deregulated. Two cases with L858R mutation enjoyed the longest PFS, among which the p44/42MAPK (Erk1/2) (137 F5) was deregulated and the pAkt (Thr308) (244 F9) was most activated compared with other five cases. (Additional file [2](#MOESM2){ref-type="media"}).

Discussion {#Sec11}
==========

Several randomized controlled trials (RCTs) have established the foundation of *EGFR*-TKI as first-line therapy in advanced NSCLC with *EGFR* mutation \[[@CR5]--[@CR8]\]. Indications for *EGFR*-TKIs have been transferred from second-line to first-line in targeted populations. However, NSCLC is a heterogeneous disease between early and advanced stages and between wild and mutant *EGFR* lung cancer. Therefore, principles for TKI therapy might be different between first-line, neoadjuvant, and adjuvant treatment \[[@CR17]\]. The use of *EGFR*-TKI in neoadjuvant treatment of NSCLC has been evaluated in limited numbers of phase II studies without survival data. Furthermore, customized NSCLC adjuvant therapy (IFCT-0801, TASTE trial) \[[@CR15]\] and systematic therapy (BATTLE) \[[@CR18]\] had validated its feasibility. Thus, biomarker-guided neoadjuvant treatment should be further evaluated in neoadjuvant settings for locally advanced but operable diseases.

To our knowledge, this is the first trial to evaluate the feasibility of biomarker-guided neoadjuvant therapy among patients with N2 NSCLC receiving TKI or chemotherapy as neoadjuvant regimen based on *EGFR* mutation status. The RR was 41.7 %, higher than 35.4 % reported in Crystalloid Versus Hydroxyethyl Starch Trial (CHEST) \[[@CR19]\] with chemotherapy alone \[[@CR20], [@CR21]\], 5--11 % with TKI alone in phase II trial in the total population \[[@CR13], [@CR14]\], and close to 46 % of the chemo-TKI sequential treatment strategy in enriched population \[[@CR22]\] (Table [3](#Tab3){ref-type="table"}). There were two cased achieving downstaging of lymph nodes (2/6), while three of seven in GC arm; and all of these five cases receiving complete resection. Besides, cases whose primary tumor responded to neoadjuvant therapy had more chances of R0 surgeries, although tumors might invade visceral pleura affecting downstaging of T.Table 3Comparison of neoadjuvant trials in lung cancerTrialPhaseTNMPopulationRegimenSampleRRChemotherapyRoth 1994 \[[@CR21]\]IIIIIATotalCEP2835 %Rosell 1994 \[[@CR20]\]IIIIIATotalMIC30--Scagliotti 2012 \[[@CR19]\] (CHEST)IIII-IIIATotalGC12935.4 %TKILara-Guerra 2009 \[[@CR13]\]IIITotalG3611 %IIIMut EGFRG650 %Schaake 2012 \[[@CR14]\]III-IIIATotalE605 %III-IIIAEnrichedE2934 %Chemo-TKILu 2013 \[[@CR22]\] (CTONG 1101)IIIIIA-N2EnrichedE + GC3946 %Bio-maker guidedZhong 2014 (CSLC 0702)IIIIIA-N2TotalE or GC2442 %IIIIIA-N2Mut EGFRE1258.3 %IIIIIA-N2WT-EGFRGC1225 %*CEP* cyclophosphamide/etoposide/cisplatin, *MIC* mitomycin/ifosfamide/cisplatin, *GC* gemcitabine/carboplatin, *E* erlotinib, *G* gefitinib, *TKI* tyrosine kinase inhibitor, *RR* response rate, *EGFR* epidermal growth factor receptor, *Mut* mutant, *WT* wild type

Overall, the PFS and OS were 7.9 and 23.2 months, respectively, similar to the INT 0139 trial in radiotherapy plus chemotherapy with/without surgical resection for stage IIIA NSCLC \[[@CR23]\]. Therefore, biomarker-guided neoadjuvant treatment strategy in patients with IIIA-N2 NSCLC based on *EGFR* mutation status is feasible.

However, benefits for improved response to neoadjuvant erlotinib therapy in this trial did not transfer to survival benefits. According to previous work \[[@CR16]\], the most common failure model in the erlotinib arm was distant metastasis (10/12). The PFS and OS did not differ significantly between two arms, although the PFS and OS tended to be longer for all patients in the GC arm. There appears to be no appropriate explanations for why TKIs are not potentially contributable to better PFS in the neoadjuvant setting but so dramatically better than chemotherapy in patients with *EGFR* mutation in the metastatic settings. In our study, an analysis of *EGFR* mutation abundance in sequential plasma samples showed that the abundance of plasma L858R dropped significantly 1 week after R0 resection, but it rebounded soon after progression (Fig. [3](#Fig3){ref-type="fig"}). Furthermore, longer PFS contributed partly to the expression of p*EGFR* and the downstream molecules (Additional file [2](#MOESM2){ref-type="media"}). Riely and colleagues also reported a rebound effect or disease flare phenomenon after discontinuing TKI in patients with advanced *EGFR* mutant NSCLC developing acquired resistance to TKI and that the optimal treatment strategy should be to add another agent to TKI or switch to systemic chemotherapeutic drugs \[[@CR24]\]. Similarly, after the termination of neoadjuvant TKI before receiving surgery in patients with IIIA-N2 disease, the sudden removal of oncogene inhibition may promote potential residual circulating tumor cells to accelerate and rebound, resulting in more aggressive diseases. So it's imperative to add standard care of neoadjuvant chemotherapy to reduce disease flare and improve complete resection rate of patients with IIIA-N2 NSCLC. Besides, this might partially explain why patients in erlobinib relapsed and developed distant metastasis with higher incidence. RADIANT study, a randomized double-blind phase III trial of adjuvant erlotinib versus placebo following complete tumor resection with/without adjuvant chemotherapy in patients with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung, reported in ASCO (American Society of Clinical Oncology, 2014) by Karen Kelly and colleagues, figured out that more patients developed brain relapse in erlotinib group than in placebo group (40.0 % vs. 12.9 %, respectively) and that no statistically significant difference of survival benefits were observed, indicating that TKIs just delay tumor recurrence rather than eliminate chances of recurrence and that poor ability of TKI permeating through blood--brain barrier results in relative lower concentration of erlotinib in central nervous system. Another recently activated trial, the ALCHEMIST study (registered on ClinicalTrials.gov as NCT02194738), aimed at comparing erlotinib and placebo as adjuvant therapy based on genetic testing. Although this study detects *EGFR* mutation status by direct sequencing which is with less sensitivity, its results indeed deserve expectation to improve tailored treatment in real world. Thus, it is warranted to combine neoadjuvant and adjuvant TKI treatment and enhance longer duration of TKI and strength of systemic chemotherapy as standard care when diseases relapse based on genetic analysis \[[@CR25]\]. In our study, there was one patient receiving surgical resection in each arm whose genetic mutation status transferred from mutant type to wild type or contrariwise (Additional file [1](#MOESM1){ref-type="media"}). Chin et al. \[[@CR26]\] figured out that first-line chemotherapy to patients with *EGFR* mutant NSCLC would decrease sensitivity to TKIs as second-line therapy. Similar work conducted by Wang J \[[@CR27]\] indicated that intra-tumoral heterogeneity may be contributable to reduced *EGFR* mutation frequency caused by chemotherapy. According to Zhou Q \[[@CR28]\], *EGFR* mutation abundance is significantly related to identity of mutation status and sensitivity of detecting methods. Gene mutation switching to *EGFR* wild type in erlotinib arm after neoadjuvant TKI therapy is possibly due to relative low abundance of *EGFR* mutation. Therefore, detecting methods with more sensitivity are extremely essential to identify pseudo-heterogeneity. Direct sequencing (DS) could detect samples with more than 10 % *EGFR* mutation frequency, whereas ARMS is with higher sensitivity (0.1--1 %) \[[@CR29]\]. However, DS was most widely used when our study was designed and activated; lowing *EGFR* mutation abundance might not be detected and potential bias could cloudy the interpretation of current data. That is why there is an ongoing study in our team to compare efficacy and accuracy of DS vs. ARMS.Fig. 3Plasma L858R abundance in the neoadjuvant TKI setting. Abbreviations: PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor. One week after the R0 resection, the abundance of plasma L858R decreased significantly, but it rebounded soon after progression. However, the PR in the first- and second-line TKI therapy did not decrease the level of plasma L858R for one case

Several limitations existed in our study. Firstly, according to clinical characteristics in Table [1](#Tab1){ref-type="table"}, smoking duration in erlotinib arm was apparently shorter than that in GC arm despite of *P* \> 0.05. However, *EGFR* mutant NSCLC is indeed different from *EGFR* wild type NSCLC involving more smokers in clinical characteristics. Besides, more genetic heterogeneity of *EGFR* mutation was observed in erlotinib, which might result in relative lower response rate of TKI and cloudy interpretation of data in our study. Our study were based on populations with different biological features, with *EGFR* mutant and wild type, which is the basic principle of biomarker-guided study design. Although biases related to non-randomized clinical trials existed, our trial contributed to neoadjuvant TKI and biomarker-guided therapy in patients with IIIA-N2 NSCLC. Furthermore, based on this trial, CTONG has launched a multicenter RCT to elucidate the role of perioperative TKIs \[CTONG1103, a national, multicenter, randomized, controlled, open-label, phase II trial of erlotinib versus GC as (neo)adjuvant therapy in stage IIIA-N2 NSCLC with EGFR mutation in exon 19 or 21 (EMERGING); registered in ClinicalTrials.gov (NCT01407822)\] in 2011. Ninety patients with resectable stage IIIA-N2 NSCLC harboring *EGFR* mutations will be randomized to neoadjuvant erlotinib arm for 42 days or GC arm for two cycles. After complete resections, patients will continue erlotinib for 1 year or the GC regimen for two cycles (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Study design of the CTONG 1103 (EMERGING). Abbreviations: NSCLC, non-small cell lung cancer; EBUS, endobronchial ultrasound; *EGFR*, epidermal growth factor receptor; ECOG, Eastern Cooperative Oncology Group; PD, progressive disease; ORR, object response rate, CR, complete response; PFS, progression-free survival; OS, overall survival; QOL, quality of life

Conclusions {#Sec12}
===========

To our knowledge, CSLC 0702 is the first phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 NSCLC based on *EGFR* mutation status with PFS and OS data. The trial met its primary outcome and validated the feasibility of this strategy. Nevertheless, erlotinib alone in neoadjuvant setting tended to show an improved response but without better PFS or OS. Brain and lung metastases were most common failure models. The role of TKIs in first-line setting of advanced NSCLC should not be simply extrapolated to neoadjuvant therapy. More RCTs combining neoadjuvant with adjuvant *EGFR*-TKI therapy in a larger population are warranted to validate the role of perioperative TKI therapy. We look forward to results of these trials to provide convincing evidences for customized therapy for patients with resectable NSCLC \[[@CR30]\].

Methods {#Sec13}
=======

Study design {#Sec14}
------------

This study, conducted in Guangdong General Hospital, China, was designed as an open-label, single-center, non-randomized, phase II clinical trial. It was approved by a local independent ethics committee and designed in accordance with Good Clinical Practice Guidelines. Written informed consents were obtained from patients before the start of treatment. Patients with resectable stage IIIA-N2 NSCLC diagnosed by mediastinoscopy or EBUS were assigned at a ratio of 1:1 to the neoadjuvant erlotinib arm or the GC arm based on *EGFR* mutation status. This study was sponsored by Chinese Society of Lung Cancer (CSLC 0702), the predecessor of Chinese Thoracic Oncology Group (CTONG), and was registered at ClinicalTrials.gov as NCT00600587.

Based on detection of mutation status, patients with mutant type *EGFR* in tumor tissue received 42-day administration of neoadjuvant erlotinib, and patients with wild type *EGFR* received an intended three cycles of GC regimen to serve as concurrent assignment. A CT scan or a positron emission tomography/computed tomography (PET/CT) was performed at 1--7 days after neoadjuvant treatment discontinuation. Patients with stable disease (SD) or a partial response (PR) underwent a thoracotomy which was scheduled to be done within 1 week after discontinuation. A radical resection of the tumor preferably by lobectomy and regional lymph node dissection with sampling of at least three N1 and three mediastinal lymph node stations was involved. Patients with progressive disease received second-line therapy or combined chemoradiotherapy. The primary outcome was response to neoadjuvant therapy. Secondary outcome measures were safety, PFS, and OS (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Flow chart. Abbreviations: NSCLC, non-small cell lung cancer; *EGFR*, epidermal growth factor receptor; E, erlotinib; GC, gemcitabine/carboplatin; PR, partial response; SD, stable disease; PD, progressive disease; NA, not available; PORT: postoperative radiotherapy; Nad,neoadjuvant; MT, mutant type; WT, wild type

Patient eligibility {#Sec15}
-------------------

Patients with newly diagnosed resectable stage IIIA-N2 NSCLC and confirmed by mediastinoscopy or EBUS (i.e., clinical T1-3 N2) were enrolled. All patients were evaluated in a multidisciplinary tumor board discussion. The diagnosis had to be histologically or cytologically confirmed with sufficient tissue samples to perform gene analysis. Candidates, having ECOG performance status of 0--1, adequate hematological and hepatic-renal functions, and qualified lung function, were required to tolerate neoadjuvant therapy and a lobectomy and radical lymph node dissection. No pregnant or breast feeding patients were included. In addition, patients with a small cell lung cancer component, any unstable systemic disease, or exposure to investigational drug therapy or other concurrent anticancer therapies outside of this trial were excluded.

Efficacy assessment {#Sec16}
-------------------

Tumor specimens and imaging data were reviewed and analyzed by the Guangdong Lung Cancer Institute. The CT or FDG-PET/CT scans were performed after study treatments were compared with baseline scans. Radiological tumor response after neoadjuvant therapy was assessed according to the Response Evaluation Criteria in Solid Tumors measurement criteria, version 1.1.

Molecular analyses {#Sec17}
------------------

DNA was extracted from formalin-fixed paraffin-embedded (FFPE) samples or frozen resection samples with macroscopically viable tumor tissue. Mutation testing was performed at the certified laboratory of Guangdong Lung Cancer Institute. *EGFR* and *KRAS* mutations in the initial biopsy, postoperative material, and recurrent tumor tissue were determined by Sanger sequencing, and *EGFR* mutations in plasma were tested using ARMS according to the protocol of the DxS *EGFR* mutation test kit (DxS). *EML4-ALK* translocation was analyzed by FISH using Vysis ALK Break Apart FISH Probe Kit according to the manufacturer's instruction. In addition, the deletion polymorphism of the Bcl-2-interacting mediator of cell death (*BIM*) gene in intron 2 was retrospectively examined by Sanger sequencing to validate its predictive role for TKI efficacy. IHC was conducted to detect the protein expressions of mutant *EGFR* and downstream molecules using rabbit mAbs from Cell Signaling Technology according to the protocols recommended by the manufacturer \[[@CR31], [@CR32]\].

Statistical analysis {#Sec18}
--------------------

Power analysis of one proportion non-inferiority was applied to provide 95 % power to declare the treatment sufficiently active for a response rate ≥42.5 % (the average of 50 % of TKI in *EGFR* mutant lung cancer and 35 % of GC regimen in neoadjuvant setting) in the biomarker-guided neoadjuvant treatment strategy and 11 % for the history reference of neoadjuvant TKI therapy \[[@CR13], [@CR19]\]. A sample size of 22 achieves 96 % power to detect a difference of −0.01 using a one-sided binomial test. The target significance level is 0.05. The actual significance level achieved is 0.0344. These results assume a baseline proportion of 0.12 and that the actual proportion is 0.417 \[[@CR33]\].

Response rates were analyzed by use of the Fisher's Exact Test. Survival was estimated with Kaplan-Meier methodology and was summarized as a median value with range and a two-sided 95 % CI. A Cox proportional hazards model was utilized to estimate hazard ratios (HR) and 95 % CI. SPSS version 21 was used for statistical analyses. All analyses were exploratory only.

Additional files {#Sec19}
================

Additional file 1:**Comparison of gene mutation status and tumor staging before and after neoadjuvant therapy and corresponding disease failure model.** Abbreviations: EGFR, epidermal growth factor receptor; LN, lymph node; GC, gemcitabine/carboplatin; PFS, progression-free survival; RT, radiotherapy; PORT, postoperative radiotherapy; RR, response rate; PR, partial response; SD, stable disease; PD, progressive disease; NA, not available; WT, wild type; BIM, BCL2L11; cT staging: primary staging of tumor before neoadjuvant therapy; cN staging: primary staging of lymph nodes before neoadjuvant therapy; pT staging: restaging of tumor based on pathological results of surgical resection; pN staging: re-staging of lymph nodes based on pathological results of surgical resection. (LOG 0 bytes).Additional file 2:**Immunohistochemistry for mutant EGFR and downstream molecules on the resected samples after induction erlotinib.** Abbreviations: EGFR, epidermal growth factor receptor; PFS, progression-free survival. Note: All six cases in the erlotinib arm that underwent resection gained partial response to tyrosine kinase inhibitor. Immunohistochemistry was conducted to detect the protein expressions on the resected samples after induction elotinib. In all the 6 cases, pEGFR (Tyr1068) has been deregulated. Cases 2 with L858R mutation enjoyed the longest PFS of 23 months, among which the p44/42MAPK (Erk1/2) (137 F5) was deregulated and the pAkt (Thr308) (244 F9) was most activated compared with other 5 cases.
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